"use strict";(self.webpackChunkstudyu_docs=self.webpackChunkstudyu_docs||[]).push([[7094],{9500:(e,t,n)=>{n.r(t),n.d(t,{assets:()=>d,contentTitle:()=>r,default:()=>u,frontMatter:()=>o,metadata:()=>i,toc:()=>l});var i=n(7850),s=n(4848),a=n(8453);const o={slug:"studyu-fab-study-antidepressant-discontinuation",title:"StudyU's Role in Easing Antidepressant Discontinuation in the FAB-Study"},r=void 0,d={authorsImageUrls:[]},l=[{value:"Unlocking the Power of N-of-1 Trials with StudyU",id:"unlocking-the-power-of-n-of-1-trials-with-studyu",level:2},{value:"Addressing the Antidepressant Discontinuation Challenge",id:"addressing-the-antidepressant-discontinuation-challenge",level:2},{value:"The FAB-Study: A Closer Look",id:"the-fab-study-a-closer-look",level:2},{value:"How StudyU supported the FAB-Study",id:"how-studyu-supported-the-fab-study",level:2},{value:"Promising Potential",id:"promising-potential",level:2},{value:"Conclusion",id:"conclusion",level:2}];function c(e){const t={a:"a",blockquote:"blockquote",h2:"h2",p:"p",strong:"strong",...(0,a.R)(),...e.components};return(0,s.jsxs)(s.Fragment,{children:[(0,s.jsxs)(t.p,{children:["We are pleased to announce the publication of the first research paper utilizing the StudyU platform\nfor a medical study. The paper ",(0,s.jsx)(t.a,{href:"https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05184-y",children:"Study protocol: combined N-of-1 trials to assess open-label placebo treatment for antidepressant discontinuation symptoms [FAB-study]"}),"\nwas published in cooperation with ",(0,s.jsx)(t.a,{href:"https://www.hsu-hh.de/",children:"Universit\xe4tsklinikum Hamburg-Eppendorf"})," and ",(0,s.jsx)(t.a,{href:"https://www.ukgm.de",children:"Universit\xe4tsklinikum Giessen und Marburg"}),",\nboth of them based in Germany."]}),"\n",(0,s.jsx)(t.p,{children:"Let us have a deeper look into the content of this innovative study and what this achievement means for StudyU."}),"\n",(0,s.jsx)(t.h2,{id:"unlocking-the-power-of-n-of-1-trials-with-studyu",children:"Unlocking the Power of N-of-1 Trials with StudyU"}),"\n",(0,s.jsxs)(t.p,{children:[(0,s.jsx)(t.strong,{children:"StudyU"})," is a novel platform leading the way in the digital transformation of N-of-1 trials, the gold standard for\nassessing personalized treatments. N-of-1 trials compare two interventions for each participant to identify the most\neffective one. Comprising the ",(0,s.jsx)(t.strong,{children:"StudyU Designer"})," for specifying and publishing trials and the ",(0,s.jsx)(t.strong,{children:"StudyU App"})," for\nparticipant engagement, the StudyU platform empowers clinicians and researchers globally to conduct secure digital\nN-of-1 trials. ",(0,s.jsx)(t.strong,{children:"StudyU"})," envisions a future of more accessible and collaborative personalized treatments, available as\na free research tool and a versatile resource for clinical practice."]}),"\n",(0,s.jsx)(t.h2,{id:"addressing-the-antidepressant-discontinuation-challenge",children:"Addressing the Antidepressant Discontinuation Challenge"}),"\n",(0,s.jsxs)(t.p,{children:["Antidepressant discontinuation is a complex issue, with many individuals facing adverse effects and symptoms that hinder\nthe process of stopping medication. This can result in unnecessary, long-term use of antidepressants. The FAB-Study\nacknowledges this challenge and proposes a solution around the concept of N-of-1 trials, which involves individual\npatients using the ",(0,s.jsx)(t.strong,{children:"StudyU App"})," to provide personalized insights into their treatment."]}),"\n",(0,s.jsx)(t.h2,{id:"the-fab-study-a-closer-look",children:"The FAB-Study: A Closer Look"}),"\n",(0,s.jsx)(t.p,{children:"The FAB-Study involves conducting a series of randomized, single-blinded N-of-1 trials. In total, 20 patients with fully\nremitted DSM-V major depressive disorder, who are experiencing moderate to severe discontinuation symptoms after\nstopping antidepressants, participate in the study."}),"\n",(0,s.jsxs)(t.p,{children:["Each N-of-1 trial consists of two cycles, each spanning eight weeks. Within these cycles, patients experience two-week\nalternating periods of open-label placebo (OLP) treatment and no treatment, in a randomized order. Their self-reported\ndiscontinuation symptoms are captured twice daily via our smartphone application, ",(0,s.jsx)(t.strong,{children:"StudyU"}),". Additionally, the study\ntracks their expectations about discontinuation symptoms and mood states."]}),"\n",(0,s.jsxs)(t.p,{children:["More information about the study is available in the open access paper: ",(0,s.jsx)(t.a,{href:"https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-023-05184-y",children:"Study protocol: combined N-of-1 trials to assess open-label placebo treatment for antidepressant discontinuation symptoms [FAB-study]"})]}),"\n",(0,s.jsx)(t.h2,{id:"how-studyu-supported-the-fab-study",children:"How StudyU supported the FAB-Study"}),"\n",(0,s.jsxs)(t.p,{children:["For the successful execution of a digital N-of-1 study, supportive and patient-friendly tools are essential. Due to the\nunique nature of N-of-1 trials and their special requirements, the N-of-trial tailored platform ",(0,s.jsx)(t.strong,{children:"StudyU"})," served as a\nparticularly helpful instrument during the implementation of the FAB-Study:"]}),"\n",(0,s.jsxs)(t.blockquote,{children:["\n",(0,s.jsx)(t.p,{children:'"The new StudyU platform greatly supported the FAB-Study, by serving as an easy-to-use and cost-effective therapeutic\ntool for us. Working with StudyU proved to be a pleasant experience for both the researchers and our patients. We will\ndefinitely consider using StudyU for future N-of-1 studies."'}),"\n",(0,s.jsx)(t.p,{children:"-Amke M\xfcller, study director of the first medical study utilizing StudyU"}),"\n"]}),"\n",(0,s.jsx)(t.h2,{id:"promising-potential",children:"Promising Potential"}),"\n",(0,s.jsx)(t.p,{children:"The results of the FAB-Study may provide valuable insights into the clinical use of open-label placebos for treating\nantidepressant discontinuation symptoms. Furthermore, the study not only addresses the clinical challenge at hand but\nalso investigates the feasibility and applicability of a series of N-of-1 trials in a clinical discontinuation trial.\nSuch insights could pave the way for more personalized, patient-centric treatments."}),"\n",(0,s.jsx)(t.p,{children:"As N-of-1 studies become more widespread, digital N-of-1 platforms could play a vital role in the future in supporting\npersonalized healthcare. They provide the infrastructure needed to streamline the trial process, from specifying\ninterventions to real-time data collection and analysis. In addition, digital N-of-1 platforms play a key role in the\nadoption of N-of-1 studies, as traditional analog methods had limitations in their implementation."}),"\n",(0,s.jsxs)(t.p,{children:["With digital platforms, such as ",(0,s.jsx)(t.strong,{children:"StudyU"}),", trials can be conducted remotely or via smartphones, enhancing participant\nengagement and ensuring the accuracy and integrity of the data. The scalability and efficiency they offer make N-of-1\ntrials more accessible and practical for personalized treatment assessment, holding great promise for the future of\nhealthcare."]}),"\n",(0,s.jsx)(t.h2,{id:"conclusion",children:"Conclusion"}),"\n",(0,s.jsxs)(t.p,{children:["As the developers of the ",(0,s.jsx)(t.strong,{children:"StudyU"})," platform, we are pleased to see ",(0,s.jsx)(t.strong,{children:"StudyU"})," being actively used in health research.\nIt makes us proud to see how ",(0,s.jsx)(t.strong,{children:"StudyU"})," contributes to an important research topic in the field of antidepressant\ndiscontinuation. The FAB study is an example of the potential of personalized medicine and the central role ",(0,s.jsx)(t.strong,{children:"StudyU"}),"\ncan play in this area."]}),"\n",(0,s.jsxs)(t.p,{children:["For us, the paper represents a significant step toward enhancing healthcare and improving the lives of patients. We are\nexcited about the future and the possibilities that personalized healthcare, powered by technologies like ",(0,s.jsx)(t.strong,{children:"StudyU"}),", holds."]})]})}function u(e={}){const{wrapper:t}={...(0,a.R)(),...e.components};return t?(0,s.jsx)(t,{...e,children:(0,s.jsx)(c,{...e})}):c(e)}},8453:(e,t,n)=>{n.d(t,{R:()=>o,x:()=>r});var i=n(6540);const s={},a=i.createContext(s);function o(e){const t=i.useContext(a);return i.useMemo((function(){return"function"==typeof e?e(t):{...t,...e}}),[t,e])}function r(e){let t;return t=e.disableParentContext?"function"==typeof e.components?e.components(s):e.components||s:o(e.components),i.createElement(a.Provider,{value:t},e.children)}},7850:e=>{e.exports=JSON.parse('{"permalink":"/blog/studyu-fab-study-antidepressant-discontinuation","source":"@site/blog/2023-10-16-studyu-fab-study-antidepressant-discontinuation.md","title":"StudyU\'s Role in Easing Antidepressant Discontinuation in the FAB-Study","description":"We are pleased to announce the publication of the first research paper utilizing the StudyU platform","date":"2023-10-16T00:00:00.000Z","tags":[],"readingTime":3.775,"hasTruncateMarker":true,"authors":[],"frontMatter":{"slug":"studyu-fab-study-antidepressant-discontinuation","title":"StudyU\'s Role in Easing Antidepressant Discontinuation in the FAB-Study"},"unlisted":false,"prevItem":{"title":"Innovative Anti-Stress Study among Physicians at Charit\xe9","permalink":"/blog/anti-stress-study-among-physicians"},"nextItem":{"title":"Introducing StudyU to the German Federal Minister of Health","permalink":"/blog/federal-health-minister-meets-studyu"}}')}}]);